5 10 15 20 25 30 35 40 45 50 • Schoechl<strong>in</strong> C, Engel R. Meta-analysis of pharmacotherapeutic trials # Handbook of alcoholism. Zernig G, Saria A, Kurz, M, O'Malley, S, Stephanie S (Ed); pp. 339 -351. Boca Raton, FL, US: CRC Press 2002, 492 pp. • Chick J, Lehert P, Landron F. Does acamprosaat improve reduction of dr<strong>in</strong>k<strong>in</strong>g as well as aid<strong>in</strong>g abst<strong>in</strong>ence? Journal of pPsychopharmacology 17[4], 397-402. • Lesch O, Walter H. 1996. Subtypes of alcoholism and their role <strong>in</strong> therapy. Alcohol and Alcohol 31 (supp 1): 63-67. • Chick J, Howlett H, Morgan M, Ritson B. 2000a United K<strong>in</strong>gdom multicentre acamprosaat study (UK- MAS): a sixth -month prospective study of acamprosaat versus placebo <strong>in</strong> prevent<strong>in</strong>g relapse after withdrawal of alcohol. Alcohol and Alcohol 35: 176 -187. • Verheul R, Lehert P, Geerl<strong>in</strong>gs PJ, Koeter MW, van den Br<strong>in</strong>k W. 2004 Predictors of acamprosaat efficay: results from a pooled analyssis of seven Europian trials <strong>in</strong>clud<strong>in</strong>g 1485 alcohol-dependent patients. Psychopharmacology (Berl), 2005 Mar; 178 (2-3): 167-173. Epub 2004 Aug 19. • Ladewig D, Knecht T, Lehert P. 1993 Acamprosaat a stabiliz<strong>in</strong>g factor <strong>in</strong> long-term withdrawal of alcoholic patients. Therapeutische Umschau, 50, 182-188. • Sass H, Soyka M, Mann K, Zieglansberger W. 1996 Relapse prevention by acamprosaat. Results from a placebo controlled study on alcohol dependence. Archives of General Psychiatry, 53, 673-680. • Whitworth A, Fischer F, Lesch O, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, fleischhacker W. 1996 Comparison of acamprosaat and placebo <strong>in</strong> long-term treatment of alcohol dependence. Lancet, 347, 1438-1442. • Poldrugo, F. (1997) Acamprosate treatment <strong>in</strong> a long-term community based alcohol rehabilitation programme. Addiction, 92, 1537-1546. • Kiefer F, Wiedeman K. 2004 Comb<strong>in</strong>ed Therapy: What Does Acamprosate And Naltrexone Comb<strong>in</strong>ation Tell Us? Alcohol and Alcoholism Vol. 39, No.6, pp. 542-547. • Kiefer F, Tarnaske T. et al. 2003a Compar<strong>in</strong>g and comb<strong>in</strong><strong>in</strong>g naltrexone and acamprosate <strong>in</strong> relapse prevention of alcoholism: a double-bl<strong>in</strong>d, placebo-controlled study. Archives of General Psychiatry 60, 92-99. • Bessonj, Aeby F, Kasa A, Lehert P, Potgieter A. 1998 Comb<strong>in</strong>ed efficacy of acamprosaat and disulfiram <strong>in</strong> the treatment of alcoholism: a controlled study. Alcohol Cl<strong>in</strong> Exp Res. 1998; 22:573-579 • Gual A, Lehert P. 2001 Acamprosaat dur<strong>in</strong>g and after acute alcohol withdrawal: a double-bl<strong>in</strong>d placebocontrolled study <strong>in</strong> Spa<strong>in</strong>. Alcohol and Alcoholism, 36, 413-418. • Swift R. 1999 Drug therapy for alcohol dependence. New England Journal of Medic<strong>in</strong>e, 340, 1482-1490. • Volpicelli J, Rh<strong>in</strong>es K, Rh<strong>in</strong>es J, Volpicelli A, Alterman A, O' Brien C. 1997 Naltrexone and alcohol depence. Role of subject compliance. Archives of General Compliance, 54, 737-742 • O' Malley S, Jaffe A, Chang G, Rode S, Schottenfield R, Meyer R, Rousanville B. 1996 Six-month folluwup of naltrexone and psychotherapy for alcohol dependence. Archives of General Psychiatry, 53, 217- 224 • Anton R, Moak D, Latham P, Wald R, Malcolm R, Dias J, Roberts J. 2001 Posttreatment results of comb<strong>in</strong><strong>in</strong>g naltrexone with cognitive-behavior therapy for the treatment of alcoholism. Journal of Cl<strong>in</strong>ical Psychopharmacology, 21, 72-77. • Streeton C, Whelan G. Naltrexone. a relapse prevention ma<strong>in</strong>tenance treatment of alcohol dependendence: a meta-analysis of randomized controlled trials. Alcohol and Alcoholism Vol. 36, No 6, pp. 544- 552, 2001 • Srisurapanont M. en Ngamwong J. 2005 Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology,8, 267-280. • Krystal J, Cramer J, Krol J, Kirk G, Rosenheck R. for the Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone <strong>in</strong> the treatment of alcohol dependence. New England Journal of Medic<strong>in</strong>e, 345, 1734-1739. • Croop Rs et al. 1997 The safety profile of naltrexone <strong>in</strong> the treatment of alcoholism. Archive s Gen psychiatry 1997; 54: 1130 – 1135 • Fuller R, Branchey L, Brightwell D. 1986 Disulfiram treatment of alcoholism. A Veterans Adm<strong>in</strong>istration Cooperative study. JAMA 1986; 256:1449-1455 • Garbutt J, West S, Carey T, Lohr K, Fulton T. 1999 Pharmacological treatment of Alcohol dependence. A Review of Evidence. 1999 JAMA, vol 281, 14,1318-1326. 76 <strong>Concept</strong> multidiscipl<strong>in</strong>iare <strong>richtlijn</strong> stoornissen <strong>in</strong> het gebruik van alcohol, 2007
5 10 15 20 25 • Chick J, Gough K, Falkowski W. 1992 Disulfiram treatment of alcoholism, British Journal of Psychiatry 1992, 161, 84-89. • Chick J. Safety Issues concern<strong>in</strong>g the use of Disulfiram <strong>in</strong> Treat<strong>in</strong>g alcohol Dependence (review). Drug society 1999; 20: 427-435 (Adis International Ltd, Chester UK). • Hughes J, Cook C. 1997 The efficacy of disulfiram; a review of outcome studies. Addiction 92:81-395. • Slattery J, Chick J, Cochrane M, Godfrey C, Kohli H, Macpherson K, Parrot S, Qu<strong>in</strong>n S, S<strong>in</strong>gle A, Tochel C, Watson H. 2003 Prevention of relapse <strong>in</strong> alcohol dependence. Health Technology Assesment Report 3.Health Technology Board for Scotland, Glasgow. • Naranjo C, Bremmer K, Lanctot K 1995 Effects of citalopram and a brief psycho-social <strong>in</strong>tervention on alcohol <strong>in</strong>take, dependence and problems. Addiction 90: 87-99. • Tihonen J, Ryynanen O, Kauhanen J, Hakola H, Salaspura M. 1996 Citalopram <strong>in</strong> the treatment of alcoholism: a double bl<strong>in</strong>d placebo controlled study. Pharmacopsychiatry 29: 27-29. • Pett<strong>in</strong>ati H, Volpicelli J, Kranzler H, Luck G, Rucktalis M, Cnaan A. 2000 Sertral<strong>in</strong>e treatment for alcohol dependence: <strong>in</strong>teractive effects of medication and alcoholic subtype Alc Cl<strong>in</strong> Exp Res 24: 1041-1049. • Kranzler H, Burleson J, Korner P, Del Boca F, Bohn M, Brown J, Leibowitz N. 1995 Placebo controlled trial of fluoxet<strong>in</strong>e as adjunct to relapse prevetion <strong>in</strong> alcoholics. American Journal of Psychiatry 152: 391- 397. • Anton R. Moak D, Lathan P, Randolph W, Malcolm r, Dias J, Roberts J (2001) Post treatment results of comb<strong>in</strong><strong>in</strong>g naltrexone with cognitive-behavoir therapy for the treatment of alcoholism. J. Consult Cl<strong>in</strong> Psychpharm 21 : 72-77 • O' Malley S, Jaffe a, Chang G, Rode S, Schottenfeld R, Meyer R, Rounsaville B (1996) Six-month followup of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53: 217-231 • Johnson B (2004) Uses of topimarate <strong>in</strong> the teratment of alcohol dependence. Exp Rev Neurotherapeutics 4(5), 751-758. <strong>Concept</strong> multidiscipl<strong>in</strong>iare <strong>richtlijn</strong> stoornissen <strong>in</strong> het gebruik van alcohol, 2007 77
- Page 1 and 2:
5 Concept Multidisciplinaire richtl
- Page 3:
De in het glossarium vermelde trefw
- Page 6 and 7:
5 10 15 20 25 30 35 40 45 4.2. Wat
- Page 11 and 12:
SAMENSTELLING VAN DE WERKGROEP 5 10
- Page 13 and 14:
Concept multidiscipliniare richtlij
- Page 15 and 16:
Welke instrumenten in de eerste en
- Page 17 and 18:
5 10 Eenmalige en kortdurende inter
- Page 19 and 20:
5 10 Aangezien het er op lijkt dat
- Page 21 and 22:
5 Alcohol en de lever Patiënten me
- Page 23 and 24:
5 10 Het verdient aanbeveling om bi
- Page 25 and 26:
Concept multidiscipliniare richtlij
- Page 27 and 28:
5 richtlijn is een document waarin
- Page 29 and 30:
5 10 15 20 25 30 35 40 45 Werkwijze
- Page 31 and 32:
* Deze classificatie is alleen van
- Page 33 and 34:
Concept multidiscipliniare richtlij
- Page 35 and 36: 5 10 15 20 25 30 35 40 45 slaafde e
- Page 37 and 38: 5 10 15 20 25 30 35 40 45 - Gematig
- Page 39 and 40: Tabel 1: DSM-IV en ICD-10 diagnosti
- Page 41 and 42: Aanbeveling De DSM-IV classificatie
- Page 43 and 44: 5 10 15 20 25 30 35 40 45 3.5. Wat
- Page 45 and 46: 5 10 15 20 25 30 35 40 45 Rol van d
- Page 47 and 48: 5 10 15 20 25 30 35 40 Aanbevelinge
- Page 49 and 50: 5 10 • Finney JW, Hahn AC, Moos R
- Page 51 and 52: 5 10 15 1998). Daarom zou het beter
- Page 53 and 54: Niveau 3 Er zijn aanwijzingen dat d
- Page 55 and 56: 5 10 • Skipsey K, Burleson J, Kra
- Page 57 and 58: 5 10 derlandse huisartsenduopraktij
- Page 59 and 60: 5 10 15 20 25 30 35 - Bij mensen di
- Page 61 and 62: Tabel 1: Screeningskenmerken voor a
- Page 63 and 64: 5 van benzodiazepines. Onder de 60
- Page 65 and 66: HOOFDSTUK 5: MEDICAMENTEUZE BEHANDE
- Page 68 and 69: Niveau 1 Niveau 2 Carbamazepine is
- Page 70 and 71: 5 6.6 (betrouwbaarheidsinterval 1.2
- Page 72 and 73: 5 10 15 20 25 30 35 40 • Duncan D
- Page 75 and 76: Auteur Mate van bewijs Jaartal Ther
- Page 77 and 78: Niveau 3 Er zijn aanwijzingen dat a
- Page 79 and 80: Auteur Mate van bewijs Jaartal van
- Page 81 and 82: Conclusies Naltrexone is een effect
- Page 83 and 84: 5 10 peld aan de veronderstelde far
- Page 85: 5 10 In een gerandomiseerde dubbelb
- Page 89 and 90: farmacotherapeutische) in combinati
- Page 91 and 92: 5 10 15 20 25 30 35 De effectivitei
- Page 93 and 94: Conclusie Niveau 3 Er zijn aanwijzi
- Page 95 and 96: 5 10 re afname van 51 gr alcohol pe
- Page 97 and 98: Conclusie Niveau 1 Cognitieve gedra
- Page 99 and 100: Conclusies Niveau 1 Het aanleren va
- Page 101 and 102: 5 Een vaker onderzochte variant (Ro
- Page 103 and 104: 5 10 15 20 Aanbeveling Alleen in ge
- Page 105 and 106: 5 10 15 20 In een later artikel tek
- Page 107 and 108: 5 10 15 20 25 30 35 40 • Miller,
- Page 109 and 110: 5 10 15 20 25 30 Overzicht van de e
- Page 111 and 112: 5 Literatuur • Miller, William R.
- Page 113 and 114: Concept multidiscipliniare richtlij
- Page 115 and 116: 5 10 15 20 25 30 deze studie geen e
- Page 117 and 118: het totale behandelpakket . Er zijn
- Page 119 and 120: 5 10 15 20 25 depressie met antidep
- Page 121 and 122: 5 10 placebo. De PTSS patiënten ve
- Page 123 and 124: Conclusie Niveau 3 Het lijkt erop d
- Page 125 and 126: 5 204 dossiers van bipolaire patië
- Page 127 and 128: 5 10 15 20 25 30 35 40 45 50 • Jo
- Page 129 and 130: 5 10 15 20 25 30 35 40 45 reden was
- Page 131 and 132: 5 10 15 20 het CBR bestuurders die
- Page 133 and 134: Conclusie Niveau 3 Justitieel opgel
- Page 135 and 136: Concept multidiscipliniare richtlij
- Page 137 and 138:
wordt ook in de studie van Richmond
- Page 140 and 141:
Evidence tabel: effectiviteit van i
- Page 142 and 143:
HOOFDSTUK 11: COMPLEMENTAIRE EN ALT
- Page 144 and 145:
5 10 15 20 25 30 dies bestaan scoor
- Page 146 and 147:
HOOFDSTUK 12: OORZAKEN VAN EN RISIC
- Page 148 and 149:
5 10 15 20 25 30 ingrepen. Hetgeen
- Page 150 and 151:
1. Directe effecten van alcoholmisb
- Page 152 and 153:
5 10 Het glutaminerge systeem draag
- Page 154 and 155:
5 10 ducties. Bij gemiddeld 1-2% va
- Page 156 and 157:
5 10 15 over de optimale dosering e
- Page 158 and 159:
1980 ovpat clonidine methysergide p
- Page 160 and 161:
op vier grotere onderzoeken, uitgev
- Page 162 and 163:
5 10 Bij alcoholverslaafden ontwikk
- Page 164 and 165:
5 10 15 20 25 30 35 40 45 50 • No
- Page 166 and 167:
5 10 15 20 vergrote milt en ascites
- Page 168 and 169:
5 10 15 20 25 30 nen bij meer dan 8
- Page 170 and 171:
Conclusie Niveau 2 Genetische facto
- Page 172 and 173:
5 10 15 Cochrane analyse van 15 ger
- Page 174 and 175:
Tverdal 2003 Cohort studie, doodsoo
- Page 176 and 177:
5 10 15 20 25 van >= 32 was de mort
- Page 178 and 179:
Eiwitrijke, energierijke voeding wo
- Page 180:
5 verzadiging waren in de groep die
- Page 202 and 203:
(Functionele)Teratogeniciteit: Bloo
- Page 204 and 205:
5 10 15 meisjes, in Nederland, waar
- Page 206 and 207:
5 10 15 20 25 30 35 40 • Het verb
- Page 208:
Door middel van een meta-analyse he
- Page 211 and 212:
5 10 15 20 25 30 35 40 45 • Rehm
- Page 213:
5 10 15 20 (b.v. na vasten) een te
- Page 216 and 217:
5 10 15 20 25 Friedländer-pneumoni
- Page 218 and 219:
Tabel: Relatieve risico’s voor ve
- Page 220 and 221:
5 10 15 20 25 optreden aspiratie pn
- Page 222 and 223:
HOOFDSTUK 13: DE ROL VAN DE HUISART
- Page 224 and 225:
Conclusies Korte interventies bij m
- Page 226:
5 10 15 20 25 30 35 40 45 Aanbeveli
- Page 229 and 230:
Concept multidiscipliniare richtlij
- Page 231 and 232:
5 10 15 20 25 behandeling hiervan,
- Page 233 and 234:
Conclusies Niveau 3 Een richtlijn w
- Page 235 and 236:
5 10 15 20 25 15.2 Kernaanbevelinge
- Page 237 and 238:
5 10 15 20 25 30 Kernaanbeveling 11
- Page 240 and 241:
(overeenkomend met ca. 10 gram pure
- Page 242 and 243:
5 10 15 20 25 30 biopsychosociale (